Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide dry-powder inhalation - AstraZeneca

Next Previous
Drug Profile

Budesonide dry-powder inhalation - AstraZeneca

Alternative Names: Budesonide inhalation powder - AstraZeneca; Pulmicort Flexhaler; Pulmicort Turbohaler; Pulmicort Turbuhaler

Latest Information Update: 20 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; AstraZeneca KK
  • Class Alcohols; Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Dioxoles; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease
  • Discontinued COVID 2019 infections

Most Recent Events

  • 01 Jun 2025 AstraZeneca completes a phase I trial (In volunteers) in USA (Inhalation, Powder) (NCT06723756)
  • 23 Jan 2025 AstraZeneca initiates a phase I trial for Healthy volunteers in USA (Inhalation, Powder) (NCT06723756)
  • 28 Sep 2022 Discontinued - Phase-II for COVID-2019 infections (In the elderly, In adults) in United Kingdom (Inhalation) (AstraZeneca pipeline, September 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top